 | | Vol. 15.04 – 6 February, 2024 |
| |
|
|
| The authors performed metabolomics of red blood cell units from 643 donors enrolled in the Recipient Epidemiology and Donor Evaluation Study. Units were tested on storage days 10, 23, and 42 for a total of 1929 samples and characterized for end-of-storage hemolytic propensity after oxidative and osmotic insults.
[Blood] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators described the development of a VHH-based bioassay that can distinguish cleaved Von Willebrand factor (VWF) from intact and ADAMTS13-cleaved VWF in plasma.
[Blood] |
|
|
|
| Researchers developed an experimental and bioinformatic approach to evaluating the quantitative association between gene expression and blood cell production across individual HSCs.
[Science Advances] |
|
|
|
| Scientists applied mild folate depletion to human and mouse erythroid cell lines and primary murine erythroid progenitors.
[Science Advances] |
|
|
|
| An unbiased proteomic assessment of infected erythrocytes and plasma samples from 24 Beninese children was performed to study the complex mechanisms underlying cerebral malaria.
[EMBO Molecular Medicine] |
|
|
|
| Scientists developed up to clinical readiness a new HSC gene therapy approach for Mucopolysaccharidosis type II that benefitted from a novel highly effective transduction protocol.
[Molecular Therapy] |
|
|
|
| Researchers engineered human T cells to express a chimeric autoantibody receptor (CAAR) with GPIbα constructed into the ligand-binding domain fused to the CD8 transmembrane domain and CD3ζ-4-1BB signaling domains.
[Haematologica] |
| |
|
|
| The authors aimed to determine the clinical benefit of tabelecleucel in patients with relapsed or refractory Epstein–Barr virus-positive post-transplant lymphoproliferative disease following HSCT or solid organ transplant.
[Lancet Oncology] |
|
|
|
| A randomized Phase II study was performed in low/int-1 risk myelodysplastic syndrome to study efficacy and safety of lenalidomide without or with ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9.
[Leukemia] |
|  |
|
|
|
| The authors provide a comprehensive summary of current single-cell studies on leukemia and highlight the markers and mechanisms that show promising clinical implications for the diagnosis and treatment of leukemia.
[Experimental Hematology & Oncology] |
|
|
|
|
| This project will focus on myeloid blood cancers, which affect both the bone marrow and blood. The new project will be led by George Vassiliou, M.D., Ph.D., professor of hematologic medicine at the University of Cambridge and a senior faculty member at the Wellcome-MRC Cambridge Stem Cell Institute.
[The Leukemia & Lymphoma Society] |
|
|
|
|
| March 21 – 23, 2024
Tokyo, Japan |
|
|
|
|
|
| | University of Maryland Baltimore – Baltimore, Maryland, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Human Technopole – Milan, Italy |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
